Insider Selling: enGene Holdings Inc. (NASDAQ:ENGN) Major Shareholder Sells 4,575 Shares of Stock

enGene Holdings Inc. (NASDAQ:ENGN) major shareholder De Solidarite Des Travai Fonds sold 4,575 shares of the company’s stock in a transaction that occurred on Thursday, April 18th. The shares were sold at an average price of $15.01, for a total value of $68,670.75. Following the completion of the sale, the insider now directly owns 3,084,107 shares in the company, valued at approximately $46,292,446.07. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

De Solidarite Des Travai Fonds also recently made the following trade(s):

• On Monday, April 22nd, De Solidarite Des Travai Fonds sold 47,854 shares of enGene stock. The stock was sold at an average price of $15.00, for a total value of $717,810.00.

enGene Trading Down 3.3 %

Shares of NASDAQ:ENGN opened at $14.75 on Thursday. enGene Holdings Inc. has a 12 month low of $6.69 and a 12 month high of $43.00. The business’s 50 day moving average price is $16.23.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Vivo Capital LLC acquired a new position in enGene in the fourth quarter worth approximately $6,264,000. Omega Fund Management LLC acquired a new position in enGene in the fourth quarter worth approximately $10,441,000. BVF Inc. IL acquired a new position in enGene in the fourth quarter worth approximately $20,777,000. Finally, Fcpm Iii Services B.V. purchased a new position in enGene during the 4th quarter worth approximately $80,097,000. Institutional investors and hedge funds own 64.16% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on ENGN. Wells Fargo & Company began coverage on enGene in a research note on Monday. They set an “overweight” rating and a $30.00 price target on the stock. Guggenheim began coverage on enGene in a research note on Monday, April 15th. They set a “buy” rating and a $34.00 price target on the stock. Leerink Partnrs reaffirmed an “outperform” rating on shares of enGene in a research report on Tuesday, February 20th. Morgan Stanley began coverage on enGene in a research report on Friday, March 8th. They issued an “overweight” rating and a $40.00 target price on the stock. Finally, SVB Leerink began coverage on enGene in a research report on Tuesday, February 20th. They issued an “outperform” rating and a $31.00 price objective on the stock. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $34.40.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.